Trials Currently Enrolling New Patients

• Aspirin Desensitization in aspirin-exacerbated respiratory disease

• Study of rashes that develop in some patients after coronary artery stent placement

• Multi-Centered, Randomized, Placebo-Controlled Trial of the Safety of Influenza Vaccine in Egg Allergic Children with a History of Anaphylaxis or Severe Allergy to Egg

• Q4882g: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOSE RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, RESPONSE DURATION AND SAFETY OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA (CIU) WHO REMAIN SYMPTOMATIC DESPITE ANTIHISTAMINE TREATMENT (H1)

Trials Currently Enrolling New Patients

• Research Database for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries

• Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation

• A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and other Indications [Protocol: 10-CBA]

Trials Currently Enrolling New Patients

• Virtual HDR CyberKnife Radiosurgery for Localized Prostatic Carcinoma

• CyberKnife Stereotactic Radiosurgery for Prostate Cancer

• Allogeneic Hematopoietic Progenitor Cell Transplantation from Unrelated Donors

• Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors (An NMDP Protocol)

• A Randomized Phase III Study of Elacytarabine vs. Investigator’s Choice in Patients with Late Stage Acute Myeloid Leukemia [Protocol: CP4055-306]

• Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients using Antithymocyte Globulin and with Cladribine-Melphalan or Total Lymphoid Irradiation

• A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (Protocol CYC682-12(A2))

• A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients using ColoPrint (PARSC)

• A Randomized Phase II Open Label Study to Assess the Efficacy and Safety of Gemcitabine + Nab-Paclitaxel (Abraxane®) With or Without ODSH (2-0, 3-0 Desulfated Heparin) as First Line Treatment of Metastatic Pancreatic Cancer [Protocol: PGX-ODSH-2011-PC1]

• Circulating Tumor Cells in Cancer Patients

• A randomized, multicenter, open-label phase II study of RO5083945 in combination with FOLFIRI versus FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with KRAS wild-type or mutant metastatic colorectal cancer. (Protocol BP25438)

• A randomized, multicenter, open-label phase II study of RO5083945 in combination with FOLFIRI versus FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with KRAS wild-type or mutant metastatic colorectal cancer. (Protocol BP25438)

• Virtual HDR Cyberknife Radiosurgery for Localized Prostatic Carcinoma: A Phase II Study

Trials Not Currently Enrolling New Patients

• Scripps Polster Breast Care Center InvestigatioNal GenebanK (PINK)

• Randomized, Open-Label, Phase 3 Study of Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer of Nonsquamous Histology [H3E-US-S130]

• A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with each of the Regimens [NSABP B-40]

• NSABP PROTOCOL B-41: A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response

• A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination with Gemcitabine Compared with Gemcitabine Alone in Previously Untreated Patients with Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma [Protocol:TH-CR-404]

• A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole [Protocol: CRAD001Y2301]

• NSABP C-07: A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin with 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon

• Project Title:SWOG 9438:Total Body Irradiation, Etoposide, Cyclophosphamide, and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy with Interleukin-2 Vs. Observation for Patients with Non-Hodgkin's Lymphoma, A BMT Study, Phase III

• A Three-Arm Randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere (AC-T); Adriamycin and Taxotere (AT); and Adriamycin. Taxotere, and Cyclophosphamide (ATC) in Breast Cancer Patients with Positive Axillary Lymph Nodes (NSABP Protocol B-30)

• A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually-Optimized Conditioning Using Pharmacokinetics [PK]-directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects with Non-Hodgkin’s Lymphoma and Hodgkin’s Lymphoma, Otsuka Protocol No. 273-08-201

• A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy with a MUC1 Dendritic Cell Vaccine (CVacTM) for Epithelial Ovarian Cancer Patients in First or Second Remission [Protocol:CAN-003]

• NSABP B-35: A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy

• A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Flurouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC), in Patients with Node-Negative Breast Cancer [NSABP B-36]

• A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) every two weeks with Bevacizumab to the same Regimen without Bevacizumab for the Treatment of Patients with Resected Stages II and III Carcinoma of the Colon (NSABP C-08)

• NSABP Protocol B-38: A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC-->P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC-->PG)

• A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer [NSABP B-39]

• A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (IBCSG 24-02)

• A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel versus Trastuzumab and Paclitaxel for First Line Therapy of Metastatic Breast Cancer (#STM01-102)

• A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum (NSABP R-04)

• A Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) Chemotherapy plus Bevacizumab for Patients with Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor (NSABP C-10)

• Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial (ECOG PACCT-1 TAILORx)

• A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer (NSABP B-42)

• A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2 Overexpressing Breast Cancer (EGF105485)

• An Observational Study of AVASTIN® (Bevacizumab) in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer and Locally Advanced or Metastatic Non-Small Cell Lung (Excluding Predominant Squamous Cell Histology) [# AVF3991n]

• A Phase III Adjuvant Trial of Sequenced EC + Filgrastim + Epoetin Alfa Followed by Paclitaxel Versus Sequenced AC Followed by Paclitaxel Versus CEF as Therapy for Premenopausal Women and Early Postmenopausal Women Who Have Had Potentially Curative Surgery for Node Positive or High Risk Node Negative Breast Cancer (NCIC MA.21)

• A Double-Blind, Randomized, Placebo-controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-positive Non-Small Cell Lung Cancer [Protocol #109493]

• A Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of SNS-595 Injection in Patients at Least 60 Years of Age with Previously Untreated Acute Myeloid Leukemia [SPO-0014]

• A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab (CIRG(TRIO)011/NSABP B-44-I / B020906)

• Study of Tamoxifen and Raloxifene for the Prevention of Breast Cancer (STAR) Protocol NSABP P-2

• A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer(Protocol: E7389-A001-206)

• Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: HOMOGENOUS DOSE DISTRIBUTION

Trials Currently Enrolling New Patients

• Comprehensive Molecular and Morphologic Characterization of Circulating Endothelial Cells

• Placement of AoRTic TraNscathetER Valves Trial (The PARTNER II Trial) - The Safety and Effectiveness of the SAPIEN XT™ Transcatheter Heart Valve with NovaFlex and Ascendra 2 delivery systems (Transfemoral and Transapical) in Intermediate Risk for Aortic Valve Surgery and Patients who cannot undergo surgery [2010-12-US ]

• MagnaSafe Registry: Determining the Risk of Magnetic Resonance Imaging in the Presence of Pacemakers and Implantable Cardioverter Defibrillators

• PPP - Medtronic Product Performance Platform Study

• Patent Foramen Ovale Closure with the Amplatzer PFO Occluder in Patients with Recurrent Cryptogenic Stroke due to Presumed Paradoxical Embolism through a Patent Foramen Ovale who have Failed Conventional Drug Therapy [ACCESS]

• Prospective Randomized EVAluation of the WATCHMAN LAA Closure Device In Patients with Atrial Fibrillation Versus Long Term Warfarin Therapy (PREVAIL)[Protocol: CT1004]

• A Non-Randomized, Non-Blinded, Multi-Center, Two-Arm, Prospective IVUS-Guided Balloon Safety and Effectiveness Study in Patients Scheduled for Coronary Intervention with Stent Placement in a Native Coronary Artery (Protocol PIC-001)

• Product Performance Platform (PPP) Sub-study Attain Ability Family (AAF)

• Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (Protocol 60023344/H) - LAPTOP-HF

• A Clinical Trial Comparing Cangrelor Treatment Strategy to Clopidogrel Standard of Care Treatment in Subjects who Require Percutaneous Coronary Intervention

• St Monitoring To Detect ACS Events In ICD Patients Study (Analyze St) [Protocol: 60026829]

• Renal Denervation in Patients with Uncontrolled Hypertension SYMPLICITY HTN-3 (Protocol IP125)

• Determining The Feasibility Of Spinal Cord Neuromodulation For The Treatment Of Chronic Heart Failure (Defeat-Hf)

• A Prospective, Randomized, Double-Blinded, Active-Control And Unblinded Standard Of Care (Soc) Controlled Study To Determine The Efficacy And Safety Of Targeted Intramyocardial Delivery Of G-Csf Mobilized Autologus Cd34+ Cells For The Improvement In Total Exercise Time During Standardized Exercise Testing In Subjects With Refractory Angina Pectoris And Chronic Myocardial Ischemia(Cmi)[Protocol: 901001]

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention with Incomplete Revascularization (Protocol GS-US-259-01146)

• Comparison of Short Term vs. Long Term True Continuous ECG Monitoring (TCEM Study)

• Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy [Protocol 10-720]; The CANOPY Study

• Intracoronary Brachytherapy for Recurrent Restenosis after Multiple Drug-Eluting Stents (SCRIPPS V)

• Clinical Study Protocol: Amorcyte Study-002 Title: A Prospective Randomized Double Blinded Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients with Acute Myocardial Infarction.[Protocol:002]

• Quadripolar Pacing Post Approval Study

Trials Not Currently Enrolling New Patients

• The Genebank at Scripps Clinic Registry

• A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm.

• The PARTNER Trial: Placement of AoRTic TraNscathetER Valves Trial with Continued Access and with Post-Approval Study [Edwards Study # 2006-06-US]

• A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions (PERSEUS)

• Post-Approval Study Protocol of the St. Jude Medical Biocor™ and Biocor™ Supra Valves [Protocol 0505]

• SJM Confirm Implantable Cardiac Monitor Study [Protocol: 60020941]

• WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF)

• PROMOTE Q® CRT-D AND QUARTET™ LEFT VENTRICULAR HEART LEAD STUDY [Protocol:60024498/E]

• CHOICE: Carotid Stenting for High Surgical-Risk Patients; Evaluating Outcomes Through the CollectIon of Clinical Evidence [06-717]

• A Prospective, Randomized, Multi-Center, Double-Blind Trial To Assess The Effectiveness And Safety Of Different Durations Of Dual Anti-Platelet Therapy (DAPT) In Subjects Undergoing Percutaneous Coronary Intervention With The CYPHER® Sirolimus-Eluting Coronary Stent (CYPHER® Stent) (Protocol P09-6301)

• A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to two De Novo Coronary Artery Lesions [PLATINUM]

• The SCRIPPS DES REAL WORLD Registry: A prospective registry for the use of Cypher ™ Sirolimus-eluting stent in patients with coronary artery disease treated with percutaneous coronary interventions at Scripps Clinic

• BRADYCARE -- Advanced BRADYCARdia Device Feature Utilization and Clinical OutcomEs

• Real Time 3-Dimensional Echocardiography for Left Ventricular Lead Site Selection to Reduce Cardiac Resynchronization Therapy Non-Responder Rates [60028823/A]

• A Prospective Evaluation in a non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels TAXUS PERSEUS [S2043-PIVOT-2006]

• A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions TAXUS PERSEUS [S2037-PIVOT-2006]

• SJ4 Post Approval Study

• CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III heart failure patients

• Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration with the Endeavor Stent (SEASIDE)

• Medtronic Adaptive CRT Clinical Study

• Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients: HOMEOSTASIS II

Trials Currently Enrolling New Patients

• Strateris Cosmetic Product Test For Undereye Bags

• Pixel RF Treatment- Facial Acne Scars and Abdominal Stretch Marks

• ESPRIT: A 10-Year, Post-marketing, Observational, Registry of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (Ps)

• Assessment & Tracking of Long-Term Alefacept Safety Study: ATLAS Study [C-736]

Trials Currently Enrolling New Patients

• A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis [Protocol: 747-301]

Trials Currently Enrolling New Patients

• Trauma and the Use of Intracranial Pressure (ICP) and LICOX Monitors- Retrospective Review

• Amiodarone (PM101), for out-of-hospital cardiac arrest due to ventricular fibrillation or pulseless ventricular tachycardia (VF/VT) (Amiodarone/Lidocaine/Placebo Study ALPS).

Trials Currently Enrolling New Patients

• A Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA (Tolvaptan) 15, 30, or 60 mg QD compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized with Dilutional Hyponatremia [Protocol 156-08-275]

• A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium difficile toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium difficile toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium difficile toxin A and toxin B) in Patients Receiving Antibiotic Therapy for Clostridium difficile Infection (MODIFY I)

Trials Currently Enrolling New Patients

• A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA-containing regimens for chronic hepatitis C infection (CHC)

Trials Not Currently Enrolling New Patients

• A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection [Protocol: AI444-010-065]

• A Phase II double-blind, placebo-controlled study of two doses of EPA-E in patients with NASH [Protocol:MCH-02-001]

• Phase 2B Study of BMS-790052 in Combination with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Prior Treatment with Peginterferon Alfa plus Ribavirin Therapy [Protocol:AI444011]

• A Phase III, Randomized, Double-Blind and Placebo-Controlled Study of Once Daily BI 201335 120 mg for 24 weeks or BI 201335 240 mg for 12 weeks in Combination with Pegylated Interferon-a and Ribavirin in Treatment-Naive Patients with Genotype 1 Chronic Hepatitis C Infection

• A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection (Protocol GS-US-256-0124)

Trials Currently Enrolling New Patients

• Study of the Genetics of Healthy Aging

• Biorepository for Scripps Health [STSI]

• Metabolomics of Aging: A Sub-Study of the Healthy Elderly Active Longevity (HEAL) Cohort

• The Effect of Diflunisal (IND 68092) on Familial Amyloidosis

Trials Not Currently Enrolling New Patients

• The Migraine and Pain Study (MAPS) GeneBank at Scripps Clinic Registry [STSI]

• The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry [STSI]

• Scripps Genomic Health Initiative

Trials Currently Enrolling New Patients

• Study of the Genetics of Healthy Aging

Trials Not Currently Enrolling New Patients

• A randomized, placebo-controlled trial of pioglitazone, compared with placebo, for prevention of stroke and myocardial infarction after ischemic stroke and transient ischemic attack

• Genetic Investigation of Solid Tumors (GIST) Cohort

Trials Not Currently Enrolling New Patients

• (NSABP B-31) A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC --> T) to that of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC --> T + H) in Node Positive Breast Cancer Patients who have Tumors that Overexpress HER2

Trials Currently Enrolling New Patients

• Study of the Genetics of Healthy Aging

Trials Currently Enrolling New Patients

• TMC435-HPC-3002: A prospective 3-year virological follow-up study in subjects previously treated in a Phase IIb or Phase III study with a TMC435-containing regimen for the treatment of hepatitis C virus (HCV) infection [TMC435HPC3002]

• 1220.48: A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-a (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN/RBV treatment [Protocol:1220.48]

• New investigational study for untreated Hepatitis C Patients Coinfected with HIV

• HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network A Longitudinal, Observational Study

• A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype VX11-950-114

• Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Ritonavir-Boosted DANOPREVIR in Combination With Peginterferon Alfa-2a Plus Ribavirin in Treatment-Naive Patients and with addition of RO5024048 in Previous Null Responder Patients With Chronic Hepatitis C Genotype 1 or 4 and Compensated Cirrhosis [Protocol: NP27946]

• AI452-016- A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which BMS-914143 was Administered for the Treatment of Chronic Hepatitis C [Protocol: AI452016]

• Safety, antiviral effect and pharmacokinetics of BI 207127 in combination with BI 201335 and with or without ribavirin for 4, 16, 24, 28 or 40 weeks in patients with chronic HCV genotype 1 infection (randomized Phase Ib/II) [Protocol: 1241.21]

• Novartis Pharmaceuticals trial entitled: A multicenter, single-arm trial evaluating the safety and efficacy of DEB025/Alisporivir in combination with pegylated interferon-a2a and ribavirin (peg-IFNa2a/RBV) in protease inhibitor treatment failure patients with chronic hepatitis C genotype 1 [Protocol: CDEB025A2306]

• A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection [Protocol: GS-US-248-122]

• A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection (GS-US-248-0123)

• A Multicenter, Randomized, Double-blind, Placebo- Controlled, Phase 2b Study to Compare the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2, Ribavirin) to Triple Therapy (with VX-222-Placebo) in Subjects With Genotype 1 Chronic Hepatitis C With Compensated Cirrhosis [Protocol: VX11-222-106]

• A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in which BMS 650032 and/or BMS-790052 was Administered for the Treatment of Chronic Hepatitis C AI444 046

• A Phase II, Randomized, Multi-center, Two Part Study of the Safety and Efficacy of Double-blind, Placebo-controlled INX-08189 in Adjunctive Treatment with Peginterferon alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Study Part A, and Openlabel INX-08189 in Adjunctive (Interferon Free) Treatment with Daclatasvir and/or Ribavirin (Copegus®) in Study Part B, in Chronically-infected HCV Genotype 2 and 3 Treatment-naïve Subjects [Protocol: INH-189-003]

• An exploratory Phase IIa, randomized, open-label trial to investigate the efficacy and safety of 12 weeks or 24 weeks of TMC435 in combination with PSI-7977 with or without ribavirin in chronic hepatitis C genotype 1-infected prior null responders to peginterferon/ribavirin therapy [Protocol: TMC435HPC2002]

• A Phase II, Double-Blind Study To Evaluate The Sustained Virologic Response of RO5024048 (Mericitabine) At Two Doses In Combination With RO5190591 (Danoprevir) Boosted With Low-Dose Ritonavir (DNV/r) And Pegasys®/Copegus® With And Without 2 Weeks Of RO5024048/Pegasys®/Copegus® Lead-In, In Patients With Chronic Hepatitis C Genotype 1 Virus Infection Who Have Failed Prior Treatment With an HCV Protease Inhibitor [Protocol: NV22877]

Trials Not Currently Enrolling New Patients

• Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination with Ribavirin to Treatment-Naive Subjects with Chronic Hepatitis C Virus Infection [526HO4]

• A Randomized, Parallel Group, Dose-Ranging Study to Evaluate Efficacy , Safety, Pharmacokinetics, and Antiviral Activity of VX 222 and Teleprevir in Combination With and Without Pegasys® and Copegus® in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C [Protocol:VX09-222-103]

• A Randomized, Double-blinded, Multicenter Study to Evaluate the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys® and Copegus® for 24 weeks versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection [PROTOCOL: NV22621]

• A Randomized, Open label, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591) Boosted with Low Dose Ritonavir (danoprevir/r) in Combination with Pegasys® and Copegus® versus Pegasys® and Copegus® alone in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection [NV22776]

• A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Combination with the HCV Polymerase Inhibitor Prodrug RO5024048 and/or Pegasys® in Chronic Hepatitis C Genotype 1 Patients Who Failed with a Previous Course of Peginterferon alfa plus Ribavirin Combination Therapy [Protocol: WV21913]

• A randomized, double-blind, placebo-controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with standard of care (Peg-IFNa and Ribavirin) in hepatitis C genotype 1 treatment-naive patients [Protocol: CDEB025A2301]

• A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C virus infection [VX-950-C211]

• A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus®) and Peginterferon Alfa 2a (Pegasys®) in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS-US-196-0123)

• A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects with Chronic Genotype 1a or 1b HCV Infection (protocol GS-US-248-0132)

• INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment with a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir boosted HCV Protease Inhibitor (RO5190591/r, DNV/r) with or without Copegus in Interferon Naïve HCV Genotype 1 Infected Patients and with Copegus in Interferon Unable and Interferon Intolerant HCV Genotype 1 Infected Patients [Protocol: PP25213]

Trials Currently Enrolling New Patients

• New investigational study for untreated Hepatitis C Patients Coinfected with HIV

Trials Currently Enrolling New Patients

• Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)

Trials Currently Enrolling New Patients

• Strateris Cosmetic Product Test For Undereye Bags

• Pixel RF Treatment- Facial Acne Scars and Abdominal Stretch Marks

Trials Currently Enrolling New Patients

• A One-Year, Open-Label Study with Teduglutide for Subjects with Parenteral Nutrition-dependent Short Bowel Syndrome who Completed Study CL0600-021 (Protocol TED-C11-001)

Trials Not Currently Enrolling New Patients

• Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon B-1a) in Patients with Relapsing-Remitting Multiple Sclerosis [Protocol: 205MS301]

Trials Currently Enrolling New Patients

• A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis [WA21092B]

• A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of IPX159 in the Treatment of Moderate to Severe Restless Legs Syndrome (RLS) [Protocol: IPX159-B11-02]

• A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Trials Not Currently Enrolling New Patients

• A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Repeat Treatment (two-cycle) Study of the Safety of AGN-214868 in Patients with Postherpetic Neuralgia

Trials Currently Enrolling New Patients

• Radiosurgery or Open Surgery for Epilepsy (ROSE) Trial

Trials Not Currently Enrolling New Patients

• An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study

Trials Currently Enrolling New Patients

• Study comparing an implantable device to back surgery for leg and low back pain

Trials Currently Enrolling New Patients

• A Prospective, International, Multi-Center Study of Clinical Outcomes and Estimated Healthcare Resource Expenditures Associated with the Treatment of Obesity using the LAP-BAND® AP Adjustable Gastric Banding System

Trials Not Currently Enrolling New Patients

• ReCharge Clinical Trial: Vagal Blocking for Obesity Control [ReCharge/D01088-000]

• EMPOWER Clinical Trial: Vagal Blocking for Obesity Control

Trials Currently Enrolling New Patients

• A Prospective, Randomized, Comparative, Multicenter Clinical Study to Assess the Safety and Effectiveness of the Transcend CyPass Glaucoma Implant in Patients with Open Angle Glaucoma Undergoing Cataract Surgery [Protocol: TMI-09-01]

• Amblyopia Treatment Study ATS 17: A randomized trial of levodopa as treatment for residual amblyopia [ATS17]

• Intermittent Exotropia Study 2 (IXT2)A Randomized Clinical Trial of Observation versus Occlusion Therapy for Intermittent Exotropia

Trials Not Currently Enrolling New Patients

• A Three-Month, Randomized, Double-Masked, Parallel Group Study with a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1% / Brimonidine 0.2% compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients with Open-Angle Glaucoma and/or Ocular Hypertension [Protocol: C-10-039]

Trials Currently Enrolling New Patients

• OsseoFix Spinal Fracture System to treat Spinal Compression Fractures

• Ascension Radial Head Study [Protocol: CP- RH-002]

• CerviCore® Intervertebral Disc CONTINUED ACCESS for the Treatment of Radicular Symptoms Associated with Loss of Disc Height, Disc/Osteophyte Complex or Herniated Disc of the Cervical Spine

• An IDE Study of the Freedom Lumbar Disc in the treatment of Lumbar Degenerative Disc Disease

• Multicenter Trial of the Continuum Ceramic Bearing System in Total Hip Arthroplasty [PROTOCOL: 08-100]

• A PROSPECTIVE, MULTI-CENTER, NONRANDOMIZED STUDY TO ASSESS LUMBAR FUSION USING INTERBODY CAGES WITH AUTOGRAFT IN CONJUNCTION WITH INSTRUMENTED POSTEROLATERAL GUTTER FUSIONS USING NANOSS BA™ [2010-01]

• Process of Changing a Pain Management Protocol on an Orthopaedic Unit

• KAST Study: The Kiva™ System as a Vertebral Augmentation Treatment- A Safety and Effectiveness Trial

• Multimodality Neuromonitoring in eXtreme Lateral Interbody Fusion (XLIF)

Trials Not Currently Enrolling New Patients

• Osteocel Plus in Anterior Cervical Discectomy and Fusion (ACDF): Evaluation of Radiographic and Patient Outcomes [Protocol: NUVA.OC - 0802]

• Osteocel Plus in eXtreme Lateral Interbody Fusion (XLIF): Evaluation of Radiographic and Patient Outcomes [Protocol: NUVA.OC - 0801]

• Clinical Study to Evaluate the Safety and Effectiveness of the Aesculap Activ-L Artificial Disc in the Treatment of Degenerative Disc Disease

• KINEFLEX SPINAL SYSTEM

• A Multi-center, Prospective, Randomized, Controlled Clinical Trial Comparing the Safety and Effectiveness of PRODISC-C to Anterior Cervical Discectomy and Fusion (ACDF) Surgery in The Treatment of Symptomatic Cervical Disc Disease (SCDD) - Continued Access Study Arm

• A Radiographic and Clinical Study Evaluating a Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem Cells(Trinity Evolution™ Viable Cryopreserved Cellular Bone Matrix)1 in Patients Undergoing Anterior Cervical Discectomy and Fusion

Trials Currently Enrolling New Patients

• Study comparing an implantable device to back surgery for leg and low back pain

• mild® Decompression Alternative to Open Surgery Epidural Steroid Injection Comparative Outcomes Study (MiDAS ECO) in Patients Diagnosed with Moderate to Severe Lumbar Spinal Stenosis Exhibiting Neurogenic Claudication [Protocol; mild03]

Trials Currently Enrolling New Patients

• Neuropsychiatric Effects of Deep Brain Stimulation in Patients with Parkinson's Disease

• Open-Label,12-Month Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects

Trials Currently Enrolling New Patients

• Study of rashes that develop in some patients after coronary artery stent placement

Trials Not Currently Enrolling New Patients

• A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily in the treatment of hospitalized adults and adolescents with influenza (Protocol NAI114373)

Trials Currently Enrolling New Patients

• Virtual HDR CyberKnife Radiosurgery for Localized Prostatic Carcinoma

• CyberKnife Stereotactic Radiosurgery for Prostate Cancer

Trials Not Currently Enrolling New Patients

• Study of the Safety and Effectiveness of the Mentor Contour Profile Gel Mammary Prosthesis in Subjects who are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

• Continued Access Study of the Mentor Contour Profile Gel Breast Implant (CPG CA Study)

• Adjunct Study Protocol for Mentor Silicone Gel-Filled Mammary Prosthesis

• Mentor MemoryGel™ Post Approval Study Protocol

• Adjunct Study Protocol for Mentor Silicone Gel-Filled Mammary Prosthesis

• Adjunct Study Protocol for Mentor Silicone Gel-Filled Mammary Prosthesis

• Mentor MemoryGel™ Post Approval Study Protocol

• McGhan Medical Corporation Silicone Filled Breast Implant Adjunct Clinical Study

• Mentor MemoryGel™ Post Approval Study Protocol

• McGhan Medical Corp. Style 410 Silicone-Filled Breast Implant Clinical Study: Continued Access

• (CARE) Inamed Corporation Style 410 Silicone - Filled Breast Implant Continued Access Reconstruction/Revision Expansion (CARE) Clinical Study

• McGhan Medical Corporation Silicone-Filled Breast Implant Adjunct Clinical Study

• Study of the Safety and Effectiveness of the Mentor Becker Expander/Breast Implant in Subjects who are Undergoing Primary Breast Reconstruction

• Adjunct Study Protocol for Mentor Silicone Gel-Filled Mammary Prosthesis

Trials Currently Enrolling New Patients

• Study of rashes that develop in some patients after coronary artery stent placement

Trials Currently Enrolling New Patients

• Combined Approach to Lysis utilizing Eptifibatide (Integrilin®) and rt-PA (Activase® Alteplase, recombinant) in Acute Ischemic Stroke-Enhanced Regimen (CLEAR-ER Stroke Trial)

Trials Currently Enrolling New Patients

• New investigational drugs for alcohol dependence

• Smoking too much pot? We want to help you stop!

• Pharmacological Treatment of Cannabis Withdrawal and Dependence

• Smoking Cessation in Hospitalized Smokers II

• Medication Development for Protracted Abstinence in Alcoholism: Mifepristone vs. Placebo

Trials Not Currently Enrolling New Patients

• Medication Development for Protracted Abstinence in Alcoholism: Naltrexone Versus Acamprosate

• Neurobiology of Cannabis Dependence

• Gabapentin Treatment of Alcohol Dependence

• Naltrexone Maintenance Treatment of Alcoholism

Trials Currently Enrolling New Patients

• Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants [Venous Thromboemoblism and Mass Spectrometry-Based Untargeted Metabolomics]

• Discovery and Validation of Proteogenomic Biomarker Panels in a Prospective Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients - Transplant Proteogenomics [CTOT]